Pluristem (PSTI) Gets a Buy Rating from H.C. Wainwright

By Austin Angelo

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Pluristem (PSTIResearch Report), with a price target of $15.50. The company’s shares closed last Monday at $3.29, close to its 52-week low of $3.21.

According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.7% and a 31.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ThermoGenesis Holdings, IntelGenx Technologies, and Cellectar Biosciences.

Currently, the analyst consensus on Pluristem is a Moderate Buy with an average price target of $20.25.

See today’s analyst top recommended stocks >>

The company has a one-year high of $11.90 and a one-year low of $3.21. Currently, Pluristem has an average volume of 53.18K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies.